Methylnaltrexone: the answer to opioid-induced constipation?
Opioid-induced constipation is a significant problem particularly for end stage cancer patients, methadone users, patients suffering from chronic pain as well as surgical patients. Until recently, there were few efficacious treatment options that did not have significant side effects. Methylnaltrexone is a promising drug for the treatment of opioid-induced constipation. It is an opioid-receptor antagonist that blocks the peripheral gastrointestinal opioid receptors responsible for opioid-induced bowel dysfunction. Due to the drug's polarity, it does not cross the blood-brain barrier; therefore, it does not block the central opioid receptors, thus, retaining effective analgesia. Methylnaltrexone has been recently approved by the FDA in the subcutaneous form for the treatment of opioid-induced bowel dysfunction, whereas the intravenous and oral forms remain under investigation.
Cannom
Rebecca R
RR
Mason
Rodney J
RJ
D000701:Analgesics, Opioid / Q000009:adverse effects*; D000818:Animals; D003248:Constipation / Q000139:chemically induced* / Q000188:drug therapy* / Q000378:metabolism; D005772:Gastrointestinal Transit / Q000187:drug effects / Q000502:physiology; D006801:Humans; D009271:Naltrexone / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D000644:Quaternary Ammonium Compounds / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use
D000701:Analgesics, Opioid; D000644:Quaternary Ammonium Compounds; C032257:methylnaltrexone; D009271:Naltrexone